Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Nihonbashi Life Science HUB

25 oct 2018 9:00 a.m. - 26 oct 2018 6:00 p.m.

8F, 1-5-5 Nihonbashi-muromachi, Chuo-ku, Tokyo, 103-0022 Japan

7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

[Session 3] Abstract Session 1

Session Chair(s)

Naoki  Furuyama, DVM, PhD

Naoki Furuyama, DVM, PhD

Medical Information & Communication, Japan Medical Affairs

Takeda Pharmaceutical Company Limited, Japan

Yuji  Kumagai, MD, PhD

Yuji Kumagai, MD, PhD

Professor, Kitasato Clinical Research Center

Kitasato University Hospital, Japan

Speaker(s)

Robert  Kleiman, MD

Can we rely on automated ECG machine measurements for clinical trial decisions?

Robert Kleiman, MD

ERT, United States

Chief Medical Officer and Vice President, Global Cardiology

Georg  Ferber

Heart Rate Correction When the Drug Affects Heart Rate

Georg Ferber

Statistik Georg Ferber GmbH, Switzerland

Statistical Consultant

Sanae  Yasuda, PhD

Intensive QT investigation as standard practice in early clinical programs

Sanae Yasuda, PhD

Japan

Senior Director, Clinical Pharmacology, Medicine Development Center

Börje C. Darpö, MD, PhD

Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability

Börje C. Darpö, MD, PhD

Clario, Sweden

Chief Scientific Officer, Cardiac Safety

Jorg  Taubel, MD, FFPM

Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals

Jorg Taubel, MD, FFPM

Richmond Pharmacology, United Kingdom

Chief Executive Officer

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.